Why is 23andMe stock trending?

Summary

  • The stock of genetics research company 23andMe surged 21% in its NASDAQ debut on June 17.
  • It merged with VGAC, a special purpose acquisition company, to go public under the ticker name ME on NASDAQ.
  • The healthcare company holds an 81% stake in the combined entity.

The stock of genetics research company 23andMe (NASDAQ: ME) has been trending after it debuted on NASDAQ. Its share price surged 21% to US$13.32 on the first day of trading on June 17. The DNA testing company is one of the latest companies to go public via SPAC.

The healthcare company merged with VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company backed by Richard Branson’s Virgin Group, on June 16.

ME shareholders will have an 81% stake in the combined entity.


Also read: Novan Inc. & Senseonic Inc: Two Trending Healthcare Stocks

Source: Pixabay.


The combined entity, named 23andMe Holding Company, expects to bring new personalized healthcare and therapeutic products through genetics research.

The stock was trading at US$13.08 at 9.01 am ET on June 18, down 2.18% from the previous close. Its market cap is around US$846 million.

23AndMe is a genomics company and provides genetic testing services to customers. It analyses saliva samples study people’s ancestry, health issues, and genetic predispositions.

Time magazine had honored the company with the Innovation of the Year award in 2008.

It is the only firm to hold multiple approvals from FDA for genetic research. It has published over 180 reports on gene factors behind a wide range of diseases.


Also read: Nabriva & Protagenic: Two Pharma Stocks On Investors’ Radar

The company has raised US$592 million to expand its health and therapeutic business - part of this capital will be used for creating a genetic and phenotypic database to accelerate personalized healthcare. Over 11 million people have signed up with 23andMe for gene reports.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

   

Kalkine

Rated 4.3/5 based on 904 Reviews at Google My Business